GeneReach Biotechnology (4171) — Free Cash Flow Generation Index

Latest as of December 2025: 0.62x

GeneReach Biotechnology (4171) has a Free Cash Flow Generation Index of 0.62x as of December 2025. Free cash flow of NT$7.47 Million represents 1% of operating cash flow (NT$12.05 Million). Read total liabilities of GeneReach Biotechnology for a breakdown of total debt and financial obligations.

FCF Generation Index

0.62x
Free Cash Flow / Operating CF

Free Cash Flow

NT$7.47 Million
TWD

Operating Cash Flow

NT$12.05 Million
TWD

Capital Expenditures

NT$4.58 Million
TWD

GeneReach Biotechnology Free Cash Flow Generation Index (2018–2022)

Historical FCF Generation Index trend for GeneReach Biotechnology across 4 annual periods. Explore 4171 capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.

Annual Free Cash Flow Generation for GeneReach Biotechnology (2018–2022)

Year-by-year Free Cash Flow Generation Index for GeneReach Biotechnology. For the full company profile including market capitalisation, see 4171 market cap.

Year FCG Index Free Cash Flow (TWD) Operating CF Capital Expenditures YoY Change
2022 0.87x NT$312.73 Million NT$357.63 Million NT$44.90 Million ▼ -8.4%
2021 0.95x NT$333.20 Million NT$348.99 Million NT$15.79 Million ▲ +54.5%
2020 0.62x NT$104.95 Million NT$169.82 Million NT$64.87 Million ▲ +3.3%
2018 0.60x NT$3.44 Million NT$5.74 Million NT$2.31 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).